文献速递脊柱关节炎

英国银屑病关节炎中生物及靶向合成DMARDs序贯治疗效果的回顾性观察研究

A retrospective observational study of effectiveness of sequential biologic and targeted synthetic DMARDs in psoriatic arthritis in the UK.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

结果显示一线治疗达成PsARC的调整OR为1.91(95%CI 1.40,2.60),高于二/三线;四线及以上与二/三线无显著差异(OR 1.13,95%CI 0.84,1.55)。

要点

  • 一线b/tsDMARDs的PsARC应答几率约为二/三线的1.91倍(95%CI 1.40,2.60)。
  • 四线及以上与二/三线的PsARC应答调整OR为1.13(95%CI 0.84,1.55),无显著差异。
  • 二/三线与四线及以上在TJC/SJC基线变化上无显著差异。

核心结论

  • 在本队列中,一线b/tsDMARDs获得阳性PsARC应答的机会最高,约为二/三线的两倍。
  • 调整后,四线及以上b/tsDMARDs的PsARC应答机会与二/三线无显著差异。
  • 这表明英国队列中患者在后线治疗仍可能获得有意义的应答。

研究设计与样本

  • 多中心回顾性观察研究,22家医院提交常规门诊PsA患者接受b/tsDMARDs治疗的数据。
  • 记录每个线次基线和首次随访(12-16周)的PsARC、TJC、SJC,比较二/三线与四线及以上达成PsARC的 odds。

主要发现

  • 1459个疗程包括一线430个、二/三线633个、四线及以上396个。
  • 一线 vs 二/三线达成PsARC的调整OR为1.91(95%CI 1.40,2.60)。
  • 四线及以上 vs 二/三线达成PsARC的调整OR为1.13(95%CI 0.84,1.55)。
  • 二/三线与四线及以上在TJC/SJC基线变化上无显著差异。

关键数值与推荐

  • 一线 vs 二/三线达成PsARC的调整OR为1.91(95%CI 1.40,2.60)。
  • 四线及以上 vs 二/三线达成PsARC的调整OR为1.13(95%CI 0.84,1.55)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Evidence evaluating effectiveness of biologic and targeted synthetic DMARDs (b/tsDMARDs) in adults with PsA after exposure to three or more b/tsDMARDs is lacking. We aimed to evaluate response to sequential lines of b/tsDMARDs. METHODS: In this multicentre retrospective observational study, 22 hospitals submitted data from routine clinic appointments of patients with PsA treated with b/tsDMARDs. Purposive sampling obtained a study population exposed to advanced lines of therapy. Effectiveness outcome measures (Psoriatic Arthritis Response Criteria [PsARC]/tender joint count [TJC]/swollen joint count [SJC]) at baseline and first follow-up (12-16 weeks) for each line were recorded. Odds of achieving PsARC in 2nd/3rd line were compared with 4th+ line. RESULTS: Four hundred and thirty-seven participants (163 male, 274 female) and 1459 treatment courses were included: 430 1st line, 633 2nd/3rd line and 396 4th+ line. The adjusted odds ratio (95% CI) for achieving PsARC in 1st line vs 2nd/3rd line was 1.91 (1.40, 2.60) and 4th+ line vs 2nd/3rd line was 1.13 (0.84, 1.55). There was no significant difference in change from baseline TJC/SJC between 2nd/3rd and 4th+ lines. CONCLUSION: In this cohort the highest chance of a positive PsARC response was to 1st line b/tsDMARD: twice the chance of response vs 2nd/3rd line. The chance of a positive PsARC response to 4th+ lines of b/tsDMARD was not significantly different from 2nd/3rd lines after adjustment. This indicates that patients in a UK cohort can continue to have a meaningful response to later lines of treatment. This is the first available evidence of response to later lines of b/tsDMARD treatment in PsA.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Gollins CE, Russell A, Smith T, et al. A retrospective observational study of effectiveness of sequential biologic and targeted synthetic DMARDs in psoriatic arthritis in the UK. Rheumatology (Oxford). 2026. PMID: 41206077. doi:10.1093/rheumatology/keaf570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。